IP Library Granted Patent US 8,853,376
Granted Patent B2
US 8,853,376 · App. 13/235,222 · Granted Oct 7, 2014

Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics

Inventors: Dilara McCauley (Cambridge, MA); John L. Diener (Cambridge, MA); Charles Wilson (Concord, MA); Thomas Greene McCauley (Cambridge, MA)
Assignee: Archemix LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,853,376
App. No.
13/235,222
Granted
Oct 7, 2014
Kind
B2
Abstract

Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.

Claims (10)

1. An unpegylated or pegylated aptamer or pharmaceutically acceptable salt thereof that binds to PDGF and comprises 5′-(SEQ ID NO: 69)-PEG-(SEQ ID NO: 40)-PEG-(SEQ ID NO: 70)-3T-3′, wherein PEG is a polyethylene glycol spacer and 3T is an inverted deoxythymidine.

2. The aptamer or pharmaceutically acceptable salt of the aptamer of claim 1 , wherein the aptamer or pharmaceutically acceptable salt of the aptamer is pegylated.

3. The aptamer or pharmaceutically acceptable salt of the aptamer of claim 2 , wherein the aptamer or pharmaceutically acceptable salt of the aptamer is pegylated with a 40 kDa PEG moiety.

4. The aptamer or pharmaceutically acceptable salt of the aptamer of claim 3 , wherein the 40 kDa PEG moiety is branched.

5. The aptamer or pharmaceutically acceptable salt of the aptamer of claim 4 , wherein the aptamer or pharmaceutically acceptable salt of the aptamer comprises the following structure at its 5′ end:

where ˜˜ indicates a linker.

6. The aptamer or pharmaceutically acceptable salt of the aptamer of claim 5 , wherein the polyethylene glycol spacer is a PEG-6 spacer.

7. A composition comprising a therapeutically effective amount of the aptamer of claim 1 , 2 , 3 , 4 , 5 , or 6 , or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

8. The composition of claim 7 , further comprising a VEGF/VEGFR antagonist.

9. The composition of claim 7 , further comprising an aptamer that binds to VEGF.

Assignments (2)
MERGER Recorded Jan 10, 2012
From: ARCHEMIX CORP.
To: ARCHEMIX LLC
Reel/Frame 027510/0478 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2011
From: GRATE, DILARA; DIENER, JOHN L.; WILSON, CHARLES; MCCAULEY, THOMAS
To: ARCHEMIX CORPORATION
Reel/Frame 027339/0448 →
Continuity (8)
Division 10980211 · Nov 2, 2004
Continuation In Part 10873853 · Jun 21, 2004
Continuation In Part 10829504 · Apr 21, 2004
Continuation In Part 10826077 · Apr 15, 2004
Continuation In Part 10718833 · Nov 21, 2003
Provisional Application 60428102 · Nov 21, 2002
Provisional Application 60469628 · May 8, 2003
Related Publication 20120171304A1 · Jul 5, 2012